

ARISE-HF - effectiveness of aldose reductase therapy in prevention of progression of diabetic cardiomyopathy

Location for study

BCDiabetes 400 - 210 West Broadway, Vancouver, V5Y 3W2

Study coordinator Dr. Marla Inducil minducil@bcdiabetes.ca phone 604-628-7253 ext 7011

Principal investigators: Drs. Tom Elliott & David Lee

Eligibility:

Type 2 Diabetes

Age 40+

A1c <8.5

No previous history of angina/MI and no previous history of heart failure

Echocardiogram with EF > 45%, and further [echo & cardiopulmonary testing criteria](#)

For further non-echo detail see this [one-page document](#) provided by the sponsor.

Design & Sponsor:

multi-centre RCT, funded by Applied Therapeutics Inc.

Hypothesis:

Use of the aldose reductase inhibitor AT-001 will reduce progression of heart failure (measured by cardio-pulmonary exercise tests) in patients with underlying asymptomatic diabetic cardiomyopathy.

Intervention:

AT-001 tablets (or placebo) in doses of 1500 mg daily or 1000 mg daily for 27+ months.

Visits are every 3 months

Odds of getting each placebo: 33%

Patient reimbursement: \$20 cash per visit

Pertinent documents

[study protocol](#)

[Ethics Approval current expires 2021-Aug-18](#), [Ethics Approval original](#)

[Clinicaltrials.gov listing](#)

[Cardio-pulmonary testing protocol](#)

[One page info sheet from sponsor](#)

Short URL = <https://bit.ly/ARISE-HF>